Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

Tom Nolan reviews this week’s research Microplastics and nanoplastics (MNPs) are being found just about everywhere we look, and they have now been found in our brains. A report in Nature Medicine ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have ... including sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors. Compared to usual care, GLP-1RA use was linked ...